首站-论文投稿智能助手
典型文献
A method for distinguishing benign and malignant pulmonary nodules based on 3D dual path network aided by K-means clustering analysis
文献摘要:
In the USA, there were about 1806590 new cancer cases in 2020, and 606520 cancer deaths are expected to have occurred in 2021. Lung cancer has become the leading cause of death from cancer in both men and women (Siegel et al., 2020). Clinical studies show that the five-year survival rate of lung cancer patients after early diagnosis and treatment intervention can reach 80%, compared with that of patients having advanced lung cancer. Thus, the early diagnosis of lung cancer is a key factor to reduce mortality.
文献关键词:
作者姓名:
Dachuan GAO;Xiaodan YE;Xuewen HOU;Yang CHEN;Xue KONG;Yuanzhong XIE;Shengdong NIE
作者机构:
School of Health Science and Engineering,University of Shanghai for Science and Technology,Shanghai 200093,China;Department of Radiology,Shanghai Chest Hospital,Shanghai 200030,China;Medical Imaging Center,Tai'an Center Hospital,Tai'an 271000,China
引用格式:
[1]Dachuan GAO;Xiaodan YE;Xuewen HOU;Yang CHEN;Xue KONG;Yuanzhong XIE;Shengdong NIE-.A method for distinguishing benign and malignant pulmonary nodules based on 3D dual path network aided by K-means clustering analysis)[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2022(11):957-967,14-15
A类:
B类:
method,distinguishing,benign,malignant,pulmonary,nodules,dual,path,network,aided,by,means,clustering,analysis,In,USA,there,were,about,new,cancer,cases,deaths,expected,have,occurred,Lung,has,become,leading,cause,from,both,women,Siegel,Clinical,studies,show,that,five,year,survival,rate,lung,patients,after,early,diagnosis,treatment,intervention,reach,compared,having,advanced,Thus,key,reduce,mortality
AB值:
0.672002
相似文献
Advances in lung cancer screening and early detection
Caichen Li;Huiting Wang;Yu Jiang;Wenhai Fu;Xiwen Liu;Ran Zhong;Bo Cheng;Feng Zhu;Yang Xiang;Jianxing He;Wenhua Liang-Department of Thoracic Oncology and Surgery,the First Affiliated Hospital of Guangzhou Medical University,China National Center for Respiratory Medicine,China State Key Laboratory of Respiratory Disease&National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,Guangzhou 510120,China;Dongguan Affiliated Hospital of Southern Medical University,Dongguan People Hospital,Dongguan 523059,China;Department of Internal Medicine,Detroit Medical Center Sinai-Grace Hospital,Detroit,Michigan 48235,USA;Department of Thoracic Surgery,Nanfang Hospital of Southern Medical University,Guangzhou 510515,China;Department of Oncology,the First People's Hospital of Zhaoqing,Zhaoqing 526020,China
Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Wu Zheng;Tan Fengwei;Yang Zhuoyu;Wang Fei;Cao Wei;Qin Chao;Dong Xuesi;Zheng Yadi;Luo Zilin;Zhao Liang;Yu Yiwen;Xu Yongjie;Ren Jiansong;Shi Jufang;Chen Hongda;Li Jiang;Tang Wei;Shen Sipeng;Wu Ning;Chen Wanqing;Li Ni;He Jie-Office of Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences, Beijing 100021, China;Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;PET-CT Center, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Department of Diagnostic Radiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。